Cargando…
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
BACKGROUND: Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments. PATIENTS AND METHODS: The fil...
Ejemplares similares
-
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR
por: Assaad, Souad, et al.
Publicado: (2020) -
Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
por: Solodky, M.L., et al.
Publicado: (2020) -
Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
por: Valet, Orion, et al.
Publicado: (2021) -
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021) -
Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial
por: Fournier, Baptiste, et al.
Publicado: (2021)